Pharmacological Management of Obese PCOS

Combination Therapies

The American College of Obstetricians and Gynecologists recommends Liraglutide 1.8 mg daily for anthropometric outcomes in PCOS, as it appears superior to placebo 1
Semaglutide shows promise for anthropometric improvements in PCOS patients 1
Weekly exenatide formulations (2 mg weekly) have been studied in combination with metformin 1.5 g daily for PCOS management 2
Orlistat 120 mg three times daily combined with COCP improves anthropometric outcomes in PCOS patients, although it has no significant effect on metabolic outcomes compared to COCP alone 5, 1

The Endocrine Society suggests a target dose of 1.5-2 g daily (typically 1000 mg twice daily) for metformin monotherapy in obese PCOS patients, with a recommendation to start with 500 mg twice daily and titrate to minimize GI side effects 4, 3
Metformin decreases LDL cholesterol and triglycerides, and reduces fasting insulin and improves insulin sensitivity in PCOS patients 3, 4

The American Diabetes Association recommends assessing renal function before initiating metformin therapy, as it is contraindicated with impaired renal function 3, 4
The American College of Obstetricians and Gynecologists advises providing contraception counseling due to improved ovulation and increased pregnancy risk with metformin therapy 3, 4